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Direct androgen regulation of PDE5 gene or the lack thereof
C-S Lin1, Z Xin2, M Namiki3, M Albersen4, D Muller5 and TF Lue1
Inhibition of phosphodiesterase-5 (PDE5) is a well-known mechanism for the effective treatment of erectile dysfunction (ED).
Androgen supplementation has also been prescribed for treating ED. However, it has been widely accepted that androgen can
upregulate PDE5 expression, and thus creating a paradox in which a positive regulator of erectile function (androgen) could
possibly increase the level of a negative regulator (PDE5). To solve this paradox, we conducted a systematic search of the PubMed
and a non-systematic search of the Internet using PDE5, erectile, penis, testosterone and androgen as keywords. The retrieved
papers were analyzed for data concerning the expression and regulation of PDE5 by androgens. Human and rat PDE5A gene
sequences were retrieved from GenBank and computer-analyzed. The results showed that a putative androgen-response element
(ARE) was reported in a study of human PDE5A gene promoter, and this prompted a separate study on whether androgen regulates
PDE5 expression. The positive outcome in the latter study has since been cited in 17 review and editorial articles as the underlying
mechanism for androgen’s therapeutic effects on ED. In addition, five other research studies also reached the same conclusion. On
the other hand, two independent studies on the genome-wide searches for androgen-regulated genes did not find PDE5A as a
candidate. Sequence analysis conducted in this study also failed to find ARE in rat PDE5A gene. Two independent studies on Leydig
cells also failed to find positive regulation of PDE5 expression by androgen. Two other studies found concomitant reduction of
cavernous smooth muscle and PDE5 expression in castrated rats. One of these studies also found no effect of androgen on PDE5
expression in cultured cavernous smooth muscle cells. Thus, it appears that reduced PDE5 expression in castrated animals is due to
reduced smooth muscle content and that PDE5A gene is not directly regulated by androgens.
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INTRODUCTION
Erectile dysfunction (ED) is a prevailing health problem that
seriously impacts the quality of life of men and their spouses/
partners.1 Among many treatment options, a class of medications
known as PDE5 inhibitors have been the most effective.2 PDE5 is
an enzyme (phosphodiesterase, PDE) that catalyzes the break-
down of cyclic guanosine monophosphate (cGMP).3 In the penis,
this enzymatic activity leads to penile flaccidity, and therefore, the
inhibition of PDE5 enables penile erection that otherwise cannot
be achieved.4,5 Thus, as far as erectile function is concerned, PDE5
is a negative regulator.6
Androgen is critical for male sexual development, but whether it
is important for erectile function has been a subject of much
heated debate. In recent years, there has been a resurgence of
interest in using androgens to treat ED, and many leading experts
in this field have explicitly expressed their favorable opinion about
this practice. However, a substantial number (X17) of these
experts’ review/editorial articles also cite positive androgen
regulation of PDE5 gene as an underlying mechanism for andro-
gen’s therapeutic effects.7–23 Thus, on the one hand, androgen
supplementation is advocated as a treatment option for ED; on
the other, androgen supplementation is believed to increase the
level of PDE5, which obviously would lead to increased severity of
ED or increased difficulty to manage ED. Thus, the purpose of this
review article is to summarize all available data concerning this
issue of androgen regulation of PDE5 expression, and to offer an
explanation for why and how the paradox arose.
METHODS
Retrieval and analysis of relevant articles
To investigate how the androgen–PDE5 paradox came about, we
conducted systematic search of the PubMed and non-systematic search
of the Internet using PDE5, penis, erectile, testosterone and androgen as
keywords. Because PubMed permits search in the title and abstract fields
only, articles that contain these keywords only in the main text cannot be
located. On the other hand, Internet permits search in the main text, but
the results invariably contain too many irrelevant hits. Thus, as a
compromise, ‘best effort’ was applied to identify the relevant hits from
the Internet, which were then followed by retrieving the pertinent articles
from PubMed or from their publishers. All retrieved articles were then
searched for contents that specifically address the issue of androgen
regulation of PDE5. The positively identified articles were then analyzed
and used for discussion in this study.
Retrieval and analysis of PDE5A gene sequences
Human and rat PDE5 gene sequences were retrieved from GenBank. They
were then analyzed for sequence similarities with each other and for the
presence of the androgen-response element (ARE, 50-AGAACAnnnTGTTCT-
30—lowercase letters indicate nucleotides not critical for androgen receptor
binding)24 using the MacVector software (MacVector, Cary, NC, USA).
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BLAST search
The web-based Basic Local Alignment Search Tool (BLAST) was used to
search for similarity between sequences. Specifically, it was used to identify
the actual gene whose nucleotide sequence was used in a cited study for
the design of reverse transcription-polymerase chain reaction (PCR)
primers.
RESULTS AND DISCUSSION
Identification of a putative ARE in human PDE5 gene
PDE5 is encoded from a single gene, PDE5A, in humans, rats and
presumably all other mammals.25 Human PDE5A gene encodes
three PDE5 isoforms (A1, A2 and A3) from two alternative
promoters, PDE5A1 and PDE5A225 (Figure 1). These isoforms
differ only in the amino terminal, and except for PDE5A3 being
smooth muscle-specific, no known functional differences exist.26
The human PDE5A1 promoter consists of a 139-base pair (bp)
core sequence that confers full basal promoter activity.27
Approximately 1600 bp upstream, a putative ARE was identified
by computer-assisted sequence alignment27 (Figure 1). This
sequence, 50-AGAAAAaacTGTACT-30, differs from the consensus
ARE, 50-AGAACAnnnTGTTCT-30,24 by one nucleotide on each of the
6-bp palindromic half-sites (Figure 1). To test whether androgen
can upregulate PDE5 gene, human vascular and cavernous
smooth muscle cells were treated with dihydrotestosterone
(DHT) and then analyzed by reverse transcription-PCR. The results
were negative for all smooth muscle cells tested; therefore, the
data were not published, as stated in two review articles by the
researchers who conducted these experiments.4,26 This negative
finding was not unexpected because the putative ARE was
imperfect, and it has been shown that multiple copies of imperfect
ARE need to coexist to have functionality.28–30 As only one
imperfect ARE was identified in PDE5 gene promoter, its existence
is likely accidental, not functional.
Genome-wide searches for androgen-responsive genes
There have been two studies that conducted genome-wide
searches for androgen-responsive genes in human cells. One of
these studies employed two complimentary techniques, namely
expression profiling and chromatin immunoprecipitation, on an
immortalized human prostate epithelial cell line (HPr-1AR), which
expresses androgen receptor (AR) and is androgen-responsive.
The expression profiling technique identified 205 androgen-
responsive genes, whereas the chromatin immunoprecipitation
technique identified 524. Among the identified genes, PDE5A is
not one of them.31
The second study also employed the chromatin immunopreci-
pitation technique, but on a better-known cell line, namely the
human prostate cancer cell line LNCaP, which also expresses AR
and is androgen-responsive. This resulted in the identification of
1532 potential AR-binding sites; PDE5A is not one of them.32
Animal studies on whether PDE5 gene is regulated by androgen
Between 2004 and 2007 four papers were published from the
same laboratory that concluded that PDE5 gene was positively
regulated by androgen (Table 1).33–36 In the first paper, the
putative ARE in the human PDE5A promoter reported by Lin et al.27
was cited as incentive for investigating whether PDE5 gene was
regulated by androgen in a rabbit model of hypogonadotropic
hypogonadism (induced by treatment with GnRH analog
triptorelin).33 The results showed that PDE5 expression in the cor-
pus cavernosum was downregulated in triptorelin-treated rabbits,
and was restored by testosterone supplementation. How-
ever, it should be noted that in the western blot analysis, no
control (such as actin or glyceraldehyde 3-phosphate dehy-
drogenase) was included, and in the reverse transcription-PCR
analysis a questionable control was used. Specifically, the control
was said to be g-non-muscle actin, citing GenBank accession
number X60733 as the source for the primer pair’s nucleotide
sequences. However, X60733 is linked to a paper that reports the
nucleotide sequence of rabbit b-actin.37 Furthermore, to resolve
this discrepancy, we conducted BLAST sequence searches for the
primer pair, and the results showed that indeed they are b-, not g-,
actin sequences. In any event, b-actin is expressed in both smooth
muscle and non-muscle cells, and therefore, not an appropriate
control for testing gene expression changes in smooth muscle
cells. Specifically, it has been shown that castration led to reduced
smooth muscle content and accumulation of adipocytes in rabbit
corpus cavernosum.38 Likewise, it has also been shown that
castration resulted in the dedifferentiation of smooth muscle cells
and reduced expression of smooth muscle-specific myosin and
smoothelin in the prostate.39,40 Thus, in the corpus cavernosum or
prostate of hypogonadal animals, smooth muscle cells are replaced
by non-smooth muscle cells. These non-smooth muscle cells,
however, still express b-actin, and thus when b-actin is used as a
control, it is incapable of normalization for hypogonadism-
associated gene changes that occur specifically in smooth
muscle cells.
The above-mentioned PDE5 study also evaluated the effect of
androgens on cGMP-hydrolyzing activity in the homogenates
prepared from the corpus cavernosum of the same animal model.
The results were that triptorelin treatment significantly reduced
the activity, while testosterone supplementation not only restored
but also increased the activity. However, it should be noted that in
this experiment a questionable negative control was used.
Specifically, based on the study’s own western blot analysis that
showed little or no PDE5 expression in human uterus, rabbit
uterine homogenates were used as negative control in the cGMP-
hydrolyzing activity assay. However, the negative finding about
uterine PDE5 expression contradicts all other studies (total of 11)
that have reported uterine PDE5 expression.41–51 In these studies,
uterus from various species (human, rat and mouse) was found to
express PDE5 and/or respond to PDE5 inhibitor sildenafil.
Particularly, one of such studies was conducted by a dedicated
PDE research team, and it showed that ‘in mouse uterus phospho-
PDE5 was easily detectable’ and ‘PDE5 is phosphorylated in intact
tissues (mouse uterus) upon activation of PKG’.44 While it can be
argued that rabbit was not among the species tested positive for
uterine PDE5 expression, it is noted that in these authors’ second
androgen-PDE5 paper, rat uterus was also found to express little
PDE5.34
In the second androgen-PDE5 paper, PDE5 expression in rat
corpus cavernosum was found downregulated by castration and
restored by testosterone supplementation.34 However, like their
first paper, no control was used in the western blot analysis, and b-
2-microglobulin was used for normalization in the real-time PCR
analysis. Note that similar findings have been reported by a
separate group of researchers, but their western blot analysis was
also conducted without control.52 In the third androgen–PDE5
Figure 1. Regulatory regions of human and rat PDE5A genes.
Nucleotide sequences of human and rat PDE5A genes were retrieved
from GenBank and analyzed by the MacVector software. A1, A2 and
A3 boxes represent coding regions for PDE5A1, A2 and A3 isoforms.
‘A3?’ box represents a region having homology with human PDE5A3
sequence but not found to be transcribed. ‘ARE?’ indicates possible
androgen-responsive elements, whose sequences are shown on top
of the consensus ARE sequence, with * indicating mismatches.
Androgen and PDE5
C-S Lin et al
82
International Journal of Impotence Research (2013), 81 – 85 & 2013 Macmillan Publishers Limited
paper, PDE5 expression in the corpus cavernosum of streptozo-
tocin-induced diabetic rats and alloxan-induced diabetic rabbits
was downregulated when compared with non-diabetic counter-
parts, and this could be normalized by testosterone supplementa-
tion.35 Again, in this study no control was used in the western blot
analysis and b-2-microglobulin was used for normalization
in the real-time PCR analysis. In the fourth paper, based on real-
time PCR normalized by b-2-microglobulin, castration was
found to reduce, and testosterone supplementation restore,
PDE5 expression in rat bladder.36 In a more recent study,53
castration was found to reduce, and testosterone supplemen-
tation restore, PDE5 expression in rat prostate. In this study, real-
time PCR was normalized by ribosomal protein L19 and western
blot controlled by b-actin. Note that the evaluation of PDE5
expression in the prostate has been highly controversial, with
levels ranging from extremely low to highly abundant, and this
discrepancy also occurs between western blot and immuno-
staining analyses within this article.54
One common denominator shared by all of the above-
mentioned androgen-for-PDE5-regulation papers is the lack of
smooth muscle control. It is well known that castration causes
reduction of cavernous and prostatic smooth muscles.38,55–59 It
has also been shown that androgen supplementation increased
bladder smooth muscle content in castrated rats.60 Furthermore,
streptozotocin-induced diabetic ED has been shown to be
associated with reduced cavernous smooth muscle content.61,62
Thus, when assessing gene expression changes in the penis,
bladder and prostate of castrated and/or diabetic animals, it is
critically important to use a smooth muscle marker (for example,
a-smooth muscle actin) in western blotting and histological
analyses to determine the smooth muscle content. Indeed, in a
2005 study, which focused on the effects of icariin on gene
expression changes in the corpus cavernosum of castrated rats,
PDE5 mRNA and protein expression was found to be reduced, but
so was the smooth muscle content as determined by trichrome
staining.63 In a more recent study, which focused on the effects of
castration on PDE5 expression in the penis, the simultaneous
reduction of smooth muscle content and PDE5 protein was again
demonstrated, this time with far clearer histological images and
quantitative data, as afforded by immunofluorescence staining
with anti-a-smooth muscle actin antibody.64 Moreover, in
this study PDE5 expression was found to be unchanged in
DHT-treated cavernous smooth muscle cells, and PDE5A promoter
was unresponsive to DHT treatment. Thus, while PDE5 expression
in castrated and diabetic rats could be restored by testosterone
supplementation, the effect was likely due to restored smooth
muscle content, and not by direct androgen regulation.
Search for ARE in rat PDE5A gene
All of the above-mentioned studies that concern androgen
regulation of PDE5A gene were conducted with rats or rabbits.
However, Homo sapiens is the only species in which PDE5A gene
promoters have been functionally tested and their nucleotide
sequences positively identified.25,27,65 Thus, while a putative ARE
was identified in human PDE5A gene, whether it also exists in the
PDE5A gene of other species is unknown. In particular, as all but
one of the above-mentioned studies investigated androgen
regulation of PDE5 in the rat, it is important that we find out
whether rat PDE5A gene has the same putative ARE as human
PDE5A gene does.
Although not functionally tested, the rat PDE5A gene promoters
have been tentatively identified by nucleotide sequence analy-
sis.66 Besides, cDNAs encoding rat PDE5A1 and PDE5A2 mRNAs
have been isolated and their sequences matched to the rat PDE5A
gene sequence45 (Figure 1). In addition, although repeated efforts
to isolate the PDE5A3 cDNA were not successful, the PDE5A3-
equivalent sequence has been found in rat PDE5A gene45
(Figure 1). Thus, rat and human PDE5A genes appear to be
homologous in both nucleotide sequence and promoter arrange-
ment. To test this hypothesis, we performed sequence alignment
between human and rat PDE5A gene sequences and conducted a
search for the putative ARE in rat PDE5A gene.
First, we conducted sequence alignment between human and
rat PDE5A genes in the regions (approximately 2770 nucleotides)
upstream of their respective first exons (encoding the PDE5A1
isoform) (Figure 1). The results showed a high degree of homology
(38%), considering that these are non-transcribed sequences. We
then searched for the consensus ARE (50-AGAACAnnnTGTTCT-30)24
within the 2768-nucleotide sequence upstream of rat PDE5A1 ATG
codon. As mentioned earlier, the putative ARE in human PDE5A
gene has two mismatches out of the 12-bp palindrome of the
consensus ARE (Figure 1). However, at this search stringency, no
putative ARE could be found in rat PDE5A gene, and only when
Table 1. Studies examining androgen regulation of PDE5 expression
Publication year/
first author
Animal or
cell
Treatment Target
tissue
Assay method Assay
control
PDE5
expression
Additional notes
2004/Morelli33 Rabbit Triptorelin CC qPCR
Western
b-Actin
None
Decrease
Decrease
b-Actin mistaken for g-actin
2005/Zhang34 Rat Castration CC qPCR
Western
b-2-MG
None
Decrease
Decrease
2006/Zhang35 Rat
Rabbit
STZ
Alloxan
CC qPCR
Western
b-2-MG
None
Decrease
Decrease
2006/Armagan52 Rat Castration CC Western None Decrease
2007/Filippi36 Rat Castration Bladder qPCR b-2-MG Decrease
2009/Yang64 Rat
Rat
CSMC
Castration
DHT
CC IF, PCR, qPCR and
western
SMA
SMA
No change
No change
PDE5 promoter assay also
showed no change
2010/Andric67 Rat
Rat LC
T
Triptorelin
T
LC
LC
qPCR and western
qPCR and western
b-Actin
b-Actin
Increase
No change
No change
2011/Muller68 Rat EDS Prostate Western None Increase
2012/Zhang53 Rat Castration Prostate qPCR
Western
L19
b-Actin
Decrease
Decrease
Abbreviations: b-2MG, b-2-microglobulin; CC, corpus cavernosum; CSMC, cavernous smooth muscle cells; DHT, dihydrotestosterone; EDS, ethane dimethane
sulfonate; IF, immunofluorescence; LC, Leydig cells; PCR, reverse transcription-polymerase chain reaction; qPCR, quantitative PCR; SMA, smooth muscle actin;
STZ, streptozotocin; T, testosterone.
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the stringency was lowered to allowing five mismatches, a
sequence was found. This sequence, 50-ACAACAcccCTCTCC-30,
located 2665 bp upstream from the ATG codon of the PDE5A1
isoform, differs from the consensus sequence by one and four
nucleotides on the left and right 6-bp palindromic half-sites,
respectively (Figure 1). As both half-site sequences of the ARE are
important for AR binding (as homodimers),24 a 4-out-6 mismatch
on the right half-site points to the unlikelihood that this sequence
could be a true ARE.
Other relevant studies
A 2010 study found that, in contrast to the study by Morelli et al.,33
treatment with triptorelin had no effect on PDE5 mRNA and
protein expression in Leydig cells of the chemically induced
hypogonadal rats (Table 1).67 However, treatment with testo-
sterone did result in increases of PDE5 mRNA and protein in
Leydig cells isolated from normal or triptorelin-treated rats.67
Nevertheless, cultured Leydig cells expressed similar levels of
PDE5 when treated with increasing concentrations of testosterone
(0, 1, 10 and 20 mM).67 Thus, the increase of PDE5 expression in
testosterone-treated rats is not due to direct androgen regulation
of PDE5A gene, but probably depends on increased nitric oxide/
cGMP production.67
In a 2011 study, several cGMP pathway proteins, including
PDE5, were investigated in an androgen ablation rat model, in
which Leydig cells were transiently destroyed between 2 and 14
days after a single intraperitoneal injection of ethane dimethane
sulfonate.68 In the prostate of this rat model 43.5-fold increases
of PDE5 protein expression were noted at 7 and 14 days after
ethane dimethane sulfonate injection. Thus, while it remains
unknown why androgen ablation resulted in elevated PDE5
expression, this study demonstrated that PDE5A gene was not
positively regulated by testosterone.
In a 2011 study, androgen replacement was found to improve
lower urinary tract symptoms in hypogonadal patients with
benign prostate hyperplasia.69 This finding also contradicts the
notion that androgen is a positive regulator for PDE5 expression
because PDE5 inhibitors have been rather consistently shown to
improve lower urinary tract symptoms.54 Thus, direct positive
androgen regulation of PDE5 expression is inconsistent with
clinical findings whether in ED or lower urinary tract symptoms.
CONCLUDING REMARKS
Although direct androgen regulation of PDE5 expression has been
widely accepted,7–23 its demonstration was based on animal
studies, in which many factors can indirectly influence the
expression of a particular gene. Specifically, a decrease of gene
expression following castration does not prove direct positive
androgen regulation, neither does restoration of gene expression
by androgen supplementation. On the other hand, cell culture
studies, which permit better control of the experimental condition,
usually provide cleaner data. For example, in the case of PDE5
expression in Leydig cells, testosterone treatment was found to
upregulate PDE5 expression in animals but not in cultured cells;
and the upregulation in animals is possibly mediated by cGMP,
not a consequence of direct action by androgens.67 In the case of
PDE5 expression in cavernous smooth muscle, a decreased level in
castrated rats was found to be associated with decreased smooth
muscle content,63,64 and no change was noted in DHT-treated
vascular or cavernous smooth muscle cells.4,26,64 At the molecular
level, the existence of a single and imperfect ARE in human PDE5A
gene promoter indicates that it is non-functional,29 and this is
further supported by genome-wide studies that failed to identify
PDE5A as an androgen-regulated gene in human prostate
epithelial cells.31,32 Furthermore, searches conducted in this
study failed to identify ARE in rat PDE5A gene. Thus, androgen
regulation of PDE5A gene is likely a conclusion reached by
interpretation of experimental data that lack the critical smooth
muscle control. And, with this realization, this study hopes to have
solved the androgen-PDE5 paradox.
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